Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU
<a href="https://pixabay.com/users/Capri23auto/">Capri23auto</a> / Pixabay

Experimental Treatment for Biliary Atresia Gets Orphan Drug Designation in the EU

According to a story from Market Screener, the drug developer Albireo Pharma, Inc., recently announced that its investigational product candidate A4250 has earned Orphan Drug designation from the European Commission.…

Continue Reading
Close Menu